Select Page

 Lung Cancer Weekly News

Empower yourself with knowledge.

Weekly news updates are currently posted on our homepages, weekly news pages and sent directly to your inbox to provide up-to-date information on what has been covered in the news regarding lung cancer in the previous week.

Lung Cancer News Update

1st-of-its kind study unearths factors radiology providers can modify to boost cancer screening uptake
“A first-of-its kind new study examines factors radiology providers can modify to boost screening uptake. Challenges addressing lung cancer are well-documented: Only 5% to 21% of eligible Americans undergo low-dose CT imaging. These numbers are even worse among populations that bear a disproportionate burden of lung cancer, experts detailed in JAMA Network Open [1]. Black individuals, for instance, are 16% less likely to survive five years after a diagnosis, with worse odds of receiving LDCT.”

Dr. Eric Singhi on Why It’s Critical to Bring Practice-Changing Lung Cancer Developments to Community Oncologists
“Advancements in Oncology, held on Saturday, June 1, featured key insights on new lung cancer data presented at the annual meeting, in addition to panels on breast, gastrointestinal, and genitourinary cancers. The event focused on providing key updates for community oncologists, which was particularly important in the lung cancer setting, with multiple practice-changing updates being presented.”

Stress Related to Residing in Violent Neighborhoods May Be Tied to Aggressive Lung Cancer in Black Men
“Exposure to increased neighborhood violence may change the glucocorticoid receptor for the stress hormone cortisol and influence the aggressiveness of lung cancer, according to new findings presented by Heath et al at the Endocrine Society’s Annual Meeting & Exposition 2024.”

AI Blood Test Dependably Detects Lung Cancer
“Using artificial intelligence technology to identify patterns of DNA fragments associated with lung cancer, researchers from the Johns Hopkins Kimmel Cancer Center and other institutions have developed and validated a liquid biopsy that may help identify lung cancer earlier. In a prospective study published June 3 in Cancer Discovery, the team demonstrated that artificial intelligence technology could identify people more likely to have lung cancer based on DNA fragment patterns in the blood.”

Lung Cancer Screening Before and After a Multifaceted Electronic Health Record Intervention
“Question  Is a multifaceted lung cancer screening intervention, including a shared decision-making tool, clinician-facing reminders, narrative guidance provided in the ordering process, and patient-facing reminders, associated with improved screening-related care (care gap closure) for lung cancer screening?”

Positive results in lung cancer show benefits of subcutaneous bispecifics
“Key takeaways: Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected, researchers reported improvement in PFS and OS with subcutaneous delivery.”

Long-term Data in Patients with Metastatic Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Alterations
“TEPMETKO recently received full approval from the FDA for the above indication.2 The conversion to full FDA approval was based on data from the pre-planned confirmatory long-term follow-up analysis of Cohort C of the VISION study. TEPMETKO is the only FDA-approved once-daily oral MET inhibitor and may be dose-reduced in order to help manage adverse reactions.”

ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
“THURSDAY, June 6, 2024 (HealthDay News) — For patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves progression-free survival, according to a study published online May 31 in the Journal of the American Medical Association to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.”

Addabbo Bill Requiring Health Insurance Coverage For Lung Cancer and Breast Cancer Screening Approved by NYS Senate
“Queens, NY (June 6, 2024): New York State Senator Joseph P. Addabbo, Jr. announced his bill (S.8553C) requiring health insurance policies to provide coverage, without a co-pay or deductible for lung cancer screening, was approved by the New York State Senate.”

Lung cancer screening found to prolong lives in real-world study
“Among US veterans diagnosed with lung cancer through the Veterans Health Administration health care system, those who underwent screening before diagnosis were more likely to be diagnosed with earlier stage disease and had a higher cure rate than those who had not been screened.”

New Study Finds Most Eligible U.S. Adults not Getting Screened for Lung Cancer
“ATLANTA, June 10, 2024 — A new study led by American Cancer Society (ACS) researchers shows less than one-in-five eligible individuals in the United States were up-to-date (UTD) with recommended lung cancer screening (LCS). The screening uptake was much lower in persons without health insurance or usual source of care and in Southern states with the highest lung cancer burden. The findings are published today in JAMA (Journal of the American Medical Association) Internal Medicine.”

Lung Cancer News Update

Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
“There is more hope than ever for people diagnosed with the deadliest cancer. Declines in smoking and the advent of screening and newer drugs have transformed the outlook for patients with lung cancer, once considered a death sentence. Progress against the disease has propelled the drop in overall cancer deaths in the U.S. over the past three decades.”

Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma
“PHILADELPHIA (June 3, 2024) — Human epidermal growth factor 2 (HER2) mutations can be identified in up to 6% of non-small cell lung cancer cases where KRAS, EGFR, or ALK gene mutations are also found, according to the results of research from Temple University Hospital and Fox Chase Cancer Center presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.”

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
“First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years. Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.”

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
“57% of patients treated with Imfinzi were alive at three years in ADRIATIC Phase III trial
Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s ​Imfinzi (durvalumab) ​demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT).”

Telehealth Palliative Care Remains Beneficial in Advanced Lung Cancer
“Palliative care was determined to be equally beneficial to in-person quality-of-life visits for patients with non–small cell lung cancer (NSCLC), according to research presented at the 2024 ASCO Annual Meeting. Results from the REACH PC trial (NCT033754890) “underscore the potential to increase access to evidence based early palliative care through telehealth delivery,” stated researcher Joseph Greer, Ph.D., associate professor of psychology in the Department of Psychiatry at Harvard Medical School in Boston, during a press briefing at the conference.”

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
“Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® (adagrasib)compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-(L)1 therapy. At a median follow-up of 9.4 months, KRAZATI demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the study’s primary endpoint, as assessed by Blinded Independent Central Review (BICR) compared to docetaxel (HR: 0.58; [95% CI, 0.45-0.76]; P <0.0001).”

Lung-RADS update helps limit false-positive results, unnecessary procedures
“A comparison between Lung Imaging Reporting and Data System (Lung-RADS) version 1.1 and Lung-RADS version 2022 found the newer version helped reduce the number of false-positive screening CT examinations while still identifying malignant airway nodules. The study from Brigham and Women’s Hospital, recently published in Radiology: Cardiothoracic Imaging, demonstrated the improved diagnostic accuracy of version 2022, which may lead to a decrease in unnecessary interventions such as bronchoscopy.”

Pfizer’s Lorbrena extends life for patients with rare lung cancer
“Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a type of non-small cell lung cancer with a genetic mutation called ALK. Non-small cell lung cancers account for about 85% of lung cancer diagnoses, and ALK-positive cancers account for about 4% of those diagnoses — more than 70,000 people every year. The cancer tends to occur in younger patients who are nonsmokers.”

Gilead’s Trodelvy extends lung cancer survival by just 1.3 months in trial
“(Reuters) – Gilead Sciences’ Trodelvy improved survival by 1.3 months more than chemotherapy in previously treated patients with advanced lung cancer in a late-stage trial, a difference that was not statistically significant, the company said on Friday. Patients given Trodelvy lived for a median of 11.1 months, while those on chemotherapy lived for 9.8 months, Gilead said. The company in January said that the non-small cell lung cancer (NSCLC) trial had failed to meet its main goal of proving Trodelvy could extend survival over chemotherapy.”

Optellum showcases AI for precision lung cancer treatment at ASCO 2024
“OXFORD, United Kingdom, May 30, 2024 /PRNewswire/ — Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has launched its multimodal therapy AI guidance platform for life science research. The novel AI software and scientific results, showing potential to optimize curative lung cancer treatment, will be showcased for the first time at the 2024 ASCO Annual Meeting in Chicago (31 May—4 June).”

CT Study Links Better Five-Year Prognosis with Minor Ground Glass Opacity Component in NSCLC Lung Nodules
“In comparison to pure solid nodules in patients with non-small cell lung cancer (NSCLC), nodules with a minor ground glass opacity component were associated with over a 38 percent higher rate of recurrence-free survival. For patients with non-small cell lung cancer (NSCLC), new computed tomography (CT) research suggests the presence of minor ground glass opacity (GGO) component may indicate significantly less pathologic lymph node involvement and predict significantly improved five-year outcomes in comparison to those with pure solid lung nodules.”

Lung Cancer News Update

Low-fat diets may help lower lung cancer risk, particularly in smokers
“The relationship between obesity and cancer is clear, and researchers have also been interested in investigating whether there is a similar link between diet and cancer risk. The role of smoking in causing lung cancer has been firmly established for decades but other lifestyle factors have received less attention. A large observational study of older adults in the United States has shown that a low-fat diet is associated with a lower risk of lung cancer, and a high-fat diet is associated with a higher risk of lung cancer in smokers.”

Double lung transplants weren’t typically recommended for lung cancer patients. But a new technique developed at Northwestern has been successful.
“For decades, double lung transplants were not considered a viable option for treating lung cancer. “It had been done, but it had always failed,” said Ankit Bharat, chief of thoracic surgery at Northwestern Medicine. “When you took out the lungs, the cancer cells would spread to the rest of the body, and it would come back a matter of months after the transplant.””

Lung cancer in Asian American women: Don’t be a statistic (never smoked)
“May is AANHPI Heritage Month so it’s a good time to share again my journey from nonsmoker to lung cancer survivor. It is such an important issue to bring awareness to this little-known and potentially deadly health disparity because, according to the 2020 census, 6.2 percent or 20.6 million people identify as AANHPI (Asian American Native Hawaiian Pacific Islander).”

Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer
“With antibody-drug conjugates well established in liquid tumors, companies are pivoting their focus to treating solid tumors, such as those of the breast, prostate and lung. If ADCs can be a viable treatment option for non-small cell lung cancer (NSCLC), which is particularly challenging given its resistance to chemotherapy and radiation, it could be a significant treatment advance with huge market potential.”

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
“High-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical significance in the overall trial population. In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard-of-care chemotherapy.”

What Should Be Done When a Patient’s Lung Cancer Screening Benefit Is ‘Marginal’?
“Patients with multimorbidity and limited life expectancy are often “unaware of their higher risk of downstream harm” when accepting lung cancer screening (LCS), according to new research.”

Nivolumab Betters Event-Free Survival vs Chemo in Non-Small Cell Lung Cancer
“The inclusion of perioperative nivolumab (Opdivo) to neoadjuvant chemotherapy delivered improvements in event-free survival (EFS) compared with chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate 77T trial (NCT04025879).”

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
“As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the monoclonal antibody cabozantinib vs docetaxel after checkpoint inhibitor treatment and chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).”

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK-Positive NSCLC
“As reported in The New England Journal of Medicine by Yi‑Long Wu, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive non–small cell lung cancer (NSCLC).”

ASCO Issues Updated Guidelines for Stage IV NSCLC With and Without Driver Alterations
“Given the number of identified health disparities, the guidelines emphasize clinician awareness of treatment challenges in different populations and suggest that both health-care providers and health care systems should strive for high-quality care for vulnerable populations.”

Body Composition Changes Linked to Poor NSCLC Outcomes
“Loss in skeletal muscle (SM) and changes in density of subcutaneous adipose tissue (SAT) in male patients and female patients, respectively, have now been linked to a greater likelihood of poor outcomes following chemoimmunotherapy for non–small cell lung cancer (NSCLC), according to findings from 3 studies published online today in JAMA Oncology.”

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
“In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses). As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were ongoing.”

Study Finds Significant Inequalities in Lung Cancer Mortality in United States
““Our findings revealed significant lung cancer mortality inequalities in the [United States], based on demographic factors,” Dr. Soin and colleagues concluded. “By contextualizing these mortality shifts in the previous 22 years, our goal is to provide a larger framework of data-driven initiatives for societal and health policy changes for improving access to care, minimizing health care inequalities, and improving outcomes.””

Lung Cancer News Update

Former cigarette smokers who vape more likely to get lung cancer: study
“Former cigarette smokers who vape are more likely to get lung cancer, warns new research. People who have stubbed out the habit but who use e-cigarettes or vaping devices are more likely to develop the deadly disease than those who don’t vape, according to the findings of the Korean study.”

Disparity of the Treatment of Unresectable Non-small Cell Lung Cancer Regarding Chemotherapy: A Systematic Review and Meta-Analysis
“This study investigates disparities in chemotherapy treatment for unresectable non-small cell lung cancer (NSCLC) between urban and rural populations. Despite advancements in NSCLC treatments enhancing survival, significant inequities persist, notably in rural areas where access to care is often limited, resulting in poorer outcomes.”

Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer
“The immunotherapy has been specifically authorised for use in adults with disease progression on or after platinum-based chemotherapy.”

Emerging Biomarkers and Tumor Heterogeneity Lead the Way in Lung Cancer
“Ongoing clinical trials in small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC) are fueling excitement in the oncology community with research efforts focusing on understanding the biology and heterogeneity of SCLC, and FDA approvals in 2024 in the NSCLC setting.”

Measuring Lung Function More Accurately and More Equitably
“Removing race from equations that estimate lung function will shift the categorization of disease severity across patient populations, moving more Black individuals into an advanced disease category, according to new research led by scientists at Harvard Medical School. At the same time, more white and Hispanic people would be reclassified as having less advanced illness.”

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
“The FDA has granted breakthrough therapy designation to the investigational ALK-selective inhibitor NVL-655 as a treatment for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC), according to a press release from the developers, Nuvalent, Inc. Specifically, the designation supports the use of NVL-655 in patients who have received at least 2 prior lines of ALK tyrosine kinase inhibitors.”

Dr Liu Previews ASCO 2024 Lung Cancer Data
“Stephen V. Liu, MD, associate professor, medicine, Georgetown University, director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, discusses several studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of non–small cell lung cancer (NSCLC).”

Immunotherapy may boost survival after lung cancer surgery
“Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it’s combined with chemotherapy, a new clinical trial reports. Those who got immunotherapy before and after surgery — along with pre-surgical chemo — had a 42% lower risk of cancer progression, recurrence or death than those who only received chemo, according to findings published Wednesday in the New England Journal of Medicine.”

Breaking bad blood: How rogue neutrophils help lung cancer spread
“Lung cancer remains a leading global health concern, responsible for the highest number of cancer-related deaths worldwide. Central to its development is the tumor microenvironment, which involves a complex interplay with immune cells such as neutrophils. Initially perceived as beneficial due to their anti-tumor activities in early cancer stages, neutrophils are now understood to play a dual role, potentially enhancing cancer metastasis under the influence of the tumor surroundings.”

Lung Cancer News Update

Alectinib Approved as an Adjuvant Treatment for Lung Cancer
“Some people with non-small cell lung cancer (NSCLC) that can be removed surgically should be treated afterward with the targeted therapy alectinib (Alecensa), results from a large clinical trial suggest. Participants in the ALINA trial had tumors with changes in the ALK gene, often called ALK-positive lung cancer. Those treated with alectinib after surgery lived longer without their cancer coming back than those treated with chemotherapy after surgery, the current standard treatment.”

Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
“Treatment with the autologous tumor-infiltrating lymphocyte (TIL) cell therapy lifileucel (Amtagvi) produced responses in a small cohort of patients with heavily pretreated metastatic non–small cell lung cancer (NSCLC), including those with different mutational burdens and PD-L1 expression, according to findings from the phase 2 IOV-COM-202 study (NCT03645928) published in Cancer Discovery.”

Why do non-smoking Asian women have high rates of lung cancer? A UCSF study hopes to find out.
“A Bay Area-based study finds that 80% of Asian American women with lung cancer never smoked and researchers are trying to figure out why.”

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC
“Treatment with nivolumab (Opdivo) plus concurrent chemoradiotherapy, followed by the combination of nivolumab and ipilimumab (Yervoy) did not improve progression-free survival (PFS) vs chemoradiotherapy followed by durvalumab (Imfinzi) in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), missing the primary end point of the phase 3 CheckMate73L trial (NCT04026412).”

A blood test to help detect lung cancer? New test offered at OSF Healthcare part of trend in medicine
“CHICAGO — Julie Harris had never been tested for lung cancer. A low-dose CT scan, the only recommended screening for adults at risk of developing lung cancer, was not something she’d ever found time to do. But when her primary care doctor recently suggested a new blood test to help look for signs of the disease, Harris was intrigued. She had her blood drawn the same day, in the same building as her doctor’s appointment.”

How the Immune System Affects Drug Response in Lung Cancer Patients
“Why do some lung cancer patients respond better to the types of drugs known as tyrosine kinase inhibitors? It may have to do with those patients’ own immune systems. That’s the hypothesis being tested by University of Colorado Cancer Center member Lynn Heasley, PhD, who recently received a Merit Review Award renewal from the U.S. Department of Veterans Affairs (VA) to study the role of the immune system in patients with lung adenocarcinoma who are treated with tyrosine kinase inhibitors (TKIs).”

FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
“The FDA has granted fast track designation to SNB-101, an anti-cancer agent derived from SN-38 as nanoparticles, as a treatment for patients with small cell lung cancer (SCLC), according to a press release from the developers, SN Bioscience.”

Exacerbations Predict Poor Outcomes in Lung Cancer Patients With Idiopathic Interstitial Pneumonia
“TAKEAWAY: The overall median survival rate for the entire study population was 9.9 months; patients with acute exacerbations had significantly worse survival than those without exacerbations at all time points (hazard ratios of 5.191, 2.351, 2.416, and 2.521 at 30, 60, 90, and 120 days, respectively). The incidence of acute exacerbation was greater in patients with non–small cell lung cancer than in those with small cell lung cancer (12.6% vs 4.2%; odds ratio, 3.316). Treatment regimens specifically for non–small cell lung cancer were significant independent predictors of acute exacerbations triggered by the therapies in a multivariate analysis (odds ratio, 3.316; P = .016).”

Study seeks to evaluate military exposures on veterans’ lung cancer risk
“Recruitment has begun for a national, multisite Department of Veterans Affairs (VA) study that seeks to expand lung cancer screening eligibility, reduce the time to lung cancer diagnosis, and increase veteran engagement.”

New study links gas stoves to child asthma, lung cancer and death
“A study led by Stanford researchers says nitrogen dioxide exposure from gas stoves could be responsible for an estimated 19,000 deaths per year.”

The Importance of Telling Your Cancer Story Honestly
“With this past April being proclaimed by the White House as National Cancer Prevention and Early Detection Month and with DNA Day on the 25th, it seemed like the perfect time to share my late wife’s hereditary cancer story with the White House. The White House has a “Share Your Story” button on the Cancer Moonshot page and I was going to make sure my wife’s cancer story and how her cancer could have been prevented was shared.”

Study Identifies Disparities in End-of-Life Care for Lung Cancer Patients
“Patients with lung cancer who were Asian/Pacific Islander, Black or Hispanic experienced a higher intensity of end-of-life care compared to white patients, according to a Northwestern Medicine population-based analysis published in the Journal of Clinical Oncology.”

Video:

NU surgeons perform 1st double-lung transplant on Chicago police officer who had lung cancer, COVID

Maine lung cancer rates above national average, experts urge annual screenings

New Hope on the Horizon for Patients With SCLC
“Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, discusses ongoing research in the small cell lung cancer (SCLC) space.”

Lung Cancer News Update

Cancer Cases To Jump 77% by 2050, Report Says
“Cancer is a growing public health problem. It is the second-leading cause of death worldwide and is the leading or second-leading cause of death before age 70 in 112 countries. As the population ages and increases, the number of cancer cases will rise.”

Drug shows promise for starving out cancer cells
“Starving out tumor cells may be a promising therapy for treatment-resistant lung cancer, according to a new study published in Science Advances.”

Assumptions After a Lung Cancer Diagnosis
“After completing treatment for lung cancer and being told that I was in remission in 2020, I thought about how unique the respective journeys of patients with cancer could be. However, having never smoked, a lung cancer diagnosis was an unlikely, but common experience for many of us.”

Miniature ‘tumor farm’ may guide personalized lung cancer therapy
“Researchers developed a miniature “tumor farm” model that uses biopsied tumor cells to enable personalized, 3-D testing of the cells’ response to various lung cancer drugs.”

Reynolds Says Her Husband Benefited From Biomarker Testing
“Des Moines, Iowa — A bill Governor Reynolds has signed into law has connections to her husband’s lung cancer treatment. The law, which will go into effect July 1st, requires insurance plans to cover biomarker testing. The tests of blood or other genetic material helps doctors determine the best course of treatment for diseases like cancer. The governor’s husband, Kevin, was diagnosed with lung cancer last fall and had a biomarker test.”

Former Worker Program New Mexico Screening Expansion
“On June 5 & 6, the Office of Worker Screening and Compensation Programs is hosting two upcoming events to announce the expansion of the Department of Energy (DOE) Former Worker Medical Screening Program (FWP) for former workers at Los Alamos and Sandia National Laboratories. The event will celebrate the introduction of an early lung cancer screening program with low-dose CT scan for high-risk former DOE workers, as well as the increased availability of occupational medical screening evaluations to detect work-related diseases in all DOE former workers.”

UT Medical Center first in the South to use Cytalux, a drug that ‘lights up’ lung cancer cells
“KNOXVILLE, Tenn. — A hospital in East Tennessee is leading the way against one of the most common types of deadly cancer. The University of Tennessee Medical Center said lung cancer claims more lives in the state than any other cancer.”

Positive 5-Year Results for Gefitinib Combo in EGFR-Variant Lung Cancer
“At a median 5-year follow-up, patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC) who added chemotherapy to gefitinib continued to have strong progression-free survival (PFS) and overall survival (OS) compared with those treated with gefitinib alone, according to a research letter published in JAMA Oncology.”

American Lung Association getting Turquoise for Lung Cancer Action Week
“OMAHA – (May 1, 2024) – Next week, the American Lung Association is turning Nebraska turquoise to raise awareness of lung cancer and encourage residents to take action to end the disease. The Lung Association is also celebrating the 10th anniversary of LUNG FORCE, a nationwide movement to end lung cancer.”

Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer
“Nearly 50% of patients with pretreated, locally advanced non-small cell lung cancer harboring a KRAS G12C mutation responded to treatment with glecirasib, findings from a phase 2 study conducted in China showed.”

Moffitt Initiates Groundbreaking Clinical Trial with Oncolytic Virus for Non-Small Cell Lung Cancer
“TAMPA, Fla. — Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy. The innovative trial uses a novel oncolytic virus, MEM-288, in combination with the immune checkpoint inhibitor nivolumab.”

Video:

Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer

Lung Cancer News Update

Survey: Most Americans Have Never Had Their Homes Tested for Radon, a Leading Cause of Lung Cancer
“Three in four Americans have never had their homes tested for radon, and over half say they’re not concerned about their radon exposure, according to a new survey.”

Terminal cancer to cancer-free: ‘Lungs in a box’ technology saves Kentucky man’s life
“(LEX 18) — April is recognized as National Donate Life Month, a time to appreciate those who have given the gift of life and an opportunity to highlight the need for organ donations.”

New Guideline Recommends Chemotherapy With Immunotherapy in Advanced SCLC
“Updated guidelines acknowledge that patients with advanced small cell lung cancer (SCLC) receiving chemotherapy plus immunotherapy followed by maintenance immunotherapy have longer-term survival than those receiving chemotherapy alone. However, this approach does not apply to patients with an EGFR mutation. In addition, guidelines include the use of lurbinectedin (Zepzelca) in the second line for relapsed SCLC. These updates were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.”

Efficacy of acupuncture for cough-related symptom clusters in patients with lung cancer: A randomized controlled trial
“Highlights- Acupuncture is becoming a complementary therapy to cough management. Acupuncture can relieve the cough of lung cancer patients. Acupuncture can not relieve expectoration and shortness of breath.

Durvalumab Confirmed Beneficial After NSCLC Chemoradiotherapy
“The benefits of durvalumab have been confirmed in a new analysis that compared patient characteristics, treatment patterns, and outcomes between those who initiated adjuvant treatment with the anti–PD-L1 antibody after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) and patients who completed their CRT and did not subsequently receive durvalumab.”

Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.”

Liposomal Irinotecan Produces Similar PFS, OS as Topotecan in SCLC
“Liposomal irinotecan produced similar survival results as topotecan when used as second-line therapy in patients with small cell lung cancer (SCLC), according to research published in the Journal of Clinical Oncology. Progression-free survival (PFS) and overall survival (OS) were similar with the 2 treatments, but liposomal irinotecan produced a higher response rate and was associated with less toxicity than topotecan.”

New Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testing
“FORT MYERS, Fla., April 25, 2024 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC).”

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
“QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy. Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC. Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types.”

Study from Phoenix Children’s Research Institute Reveals New Way to Prevent Lung Cancer from Spreading
“PHOENIX , April 25, 2024 /PRNewswire/ — Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.”

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
“SHANGHAI, April 24, 2024 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.”

Tislelizumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer
“Combination therapy with the anti-PD-1 monoclonal antibody tislelizumab (Tevimbra) and chemotherapy delivered statistically significant improvements over placebo as a first-line treatment option for patients with extensive-stage small cell lung cancer (ES-SCLC), according to data from the phase 3 RATIONALE-312 study (NCT04005716).”

H.R.6693 – Lung Cancer Screening and Prevention Act of 2023
Sign up to get alerts!

Video:

The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment
“At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, argued in favor of perioperative immunotherapy in the treatment of lung cancer.”

Systemic Treatment Options for Non-Small Cell Lung Cancer
“Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.”

Lung Cancer News Update

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
“On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.”

Retired NY Police Officer Runs Boston Marathon 6 Months After Lung Cancer Surgery
“When Vinny O’Shaughnessy crossed the finish line at the Boston Marathon, he says he was the “happiest guy on earth.” Mostly happy it was over— each step of the 26.2 miles hurt because of some bruised ribs sustained in a fall while training — but also because even cancer couldn’t keep him from his goal.”

Preoperative Physical Dysfunction Characteristics and Influence Factors Among Elderly Patients with Early Lung Cancer: A Latent Class Analysis
“Conclusion: The variety of preoperative physical dysfunction seen in elderly patients with early lung cancer can be categorized into three latent classes. Medical professionals should create strategies for intervention for multiple patient populations with the goal of further enhancing their general state of life.”

Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell Lung Cancer
TAMPA, Fla. — Non-small cell lung cancer accounts for nearly 85% of all lung cancer cases. Targeted immunotherapy is a common treatment, but it does not work for everyone. However, a new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies.”

New trials show promise for immune checkpoint blockers in early-stage lung cancer
“In a recent phase I trial published in the journal Cell Reports Medicine, researchers from Belgium administered a dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC). They found that the vaccine was viable and led to limited toxicity and systemic T-cell responses, with 50% of patients experiencing disease recurrence during the study.”

A Combination of Targeted Therapies Proves Effective Against Mutation-Driven Lung Cancer
“Combining targeted therapies known as tyrosine kinase inhibitors (TKIs) can be an effective way to treat a mutation-driven form of lung cancer in cases where tumors develop resistance to treatment and where cancer has spread to other parts of the body, a University of Colorado Cancer Center member reports. “This combination has not been studied very well before, and it really has shown some impressive results,” says Tejas Patil, MD, an assistant professor in the CU Division of Medical Oncology.”

Financial Strain, Quality of Life Top Unmet Needs in Lung Cancer Survivors
““Overall, our findings suggest that unmet needs are associated with QOL and financial toxicity and highlight the potential for targeted interventions that address these needs to improve QOL and financial toxicity among survivors of lung cancer,” they concluded. “Based on our findings of unmet needs and potential interventions to improve QOL and FT and on prior research including recommendations per the National Comprehensive Cancer Network survivorship guidelines, we propose a survivorship framework adapted from Nekhlyudov et al for survivors of lung cancer.””

Video:

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
“The robotic-assisted biopsy platform Ion is a “game-changer” for patients with lung cancer, as it provides a quicker, less invasive surgical method for conducting a lung biopsy, according to Richard Lazzaro, MD. In a conversation with CancerNetwork, Lazzaro, the chief of Thoracic Surgery at the Southern Region of RWJBarnabas Health, spoke about his experience with adopting the Ion robotic bronchoscopy platform for the early detection of lung cancer at Monmouth Medical Center. He highlighted how the tool may enable practices to acquire tissue and perform disease staging with fewer complications, which may particularly benefit those who plan to undergo induction chemotherapy or immunotherapy.”

Podcast: Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment

Lung Cancer News Update

Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
“Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James).”

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer
“In the phase 3 TROPION-Lung01 study (NCT04656652), datopotamab deruxtecan (Dato-DXd; DS-1062a), a Trop-2 directed antibody drug conjugate (ADC), induced a statistically significant improvement in progression-free survival (PFS) when given as a treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, patients with squamous histology did not experience a benefit.”

FAPI-PET shows promise in patients with lung cancer
“FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of Nuclear Medicine.”

FOXP3: A Player of Immunogenetic Architecture in Lung Cancer
“The transcription factor forkhead box protein 3 (FOXP3) is considered to be a prominent component of the immune system expressed in regulatory T cells (Tregs). Tregs are immunosuppressive cells that regulate immune homeostasis and self-tolerance. FOXP3 was originally thought to be a Tregs-specific molecule, but recent studies have pinpointed that FOXP3 is expressed in a diversity of benign tumors and carcinomas. The vast majority of the data have shown that FOXP3 is correlated with an unfavorable prognosis, although there are some reports indicating the opposite function of this molecule. Here, we review recent progress in understanding the FOXP3 role in the immunogenetic architecture of lung cancer, which is the leading cause of cancer-related death. We discuss the prognostic significance of tumor FOXP3 expression, tumor-infiltrating FOXP3-lymphocytes, tumor FOXP3 in tumor microenvironments and the potential of FOXP3-targeted therapy.”

Asbestos victim’s dying words aired in wrongful death case against Buffet’s railroad
“HELENA, Mont. — Thomas Wells ran a half-marathon at age 60 and played recreational volleyball until he was 63. At 65 years old, doctors diagnosed him with mesothelioma, a rare and aggressive lung cancer linked to asbestos exposure.”

Some breast cancer patients could be at risk of another type of cancer, study reveals
“Women with breast cancer who have received chemotherapy are at an increased risk of developing lung cancer, a new study suggests. Epic Research, a health data group based in Wisconsin, found that women in this category have a 57% higher lung cancer risk than those who received radiation. In comparison to patients who received endocrine therapy, those who have undergone chemo have a 171% increase in lung cancer risk, the study found.”

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses
“We recently showed that lung tumor specific KRAS-G12C inhibition causes remodelling of the tumor immune microenvironment from cold to hot. As a result, KRAS-G12C inhibition is able to synergise with anti-PD-1 treatment, but only in tumor models that were already moderately responsive to immune checkpoint blockade at baseline.”

Research: Liquid Biopsy May Detect, Monitor Aggressive Lung Cancer
“A new lab assay developed by researchers at Fred Hutch Cancer Center could make diagnosis and treatment of small-cell lung cancer and non-small cell lung cancer easier.”

New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients
“Genialis, the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers. Genialis presented additional findings on the performance of the biomarker in predicting drug response across preclinical models and real-world clinical benefit at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 5-10, 2024.”

Bacteria in cancer unmasked
“Researchers have compiled a detailed catalogue of bacteria living in cancer metastases. Having analyzed over 4000 tumors, they shed light on the diversity of these co-inhabitants and how they might interact with cancer cells and their surroundings. For example, certain bacteria were linked to a worse response to immunotherapy. This study paves the way to a better understanding of how bacteria help or hinder cancer (therapy), and how we can use this for patients’ advantage.”

FDA Grants Fast Track Designation to PT217 in ES-SCLC
“PT217 has been granted fast track designation by the FDA for the treatment of ES-SCLC, according to Phanes Therapeutics. The process is designed to facilitate the development and speed up the review of drugs that treat serious conditions and fill unmet needs.”

Lung Cancer News Update

Study of Global Lung Cancer Deaths Points to Emerging Trends and Effects on Women
“A new study examines the causes of lung and related cancers in the 10 most populous nations, including the U.S. The findings, by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, reveal an evolving picture of global mortality from tracheal, bronchial and lung cancers (TBLC) from 1990 to 2019. The data also put the spotlight not only on tobacco use but on air pollution. “Tobacco smoking is still the most important modifiable risk factor, but air pollution has become a very important risk factor as well,” said senior author Gilberto Lopes, M.D., chief of the Division of Medical Oncology at Sylvester and associate director for the cancer center.”

Roswell Park Research Debunks Perceived Benefits of Overweight/Obesity in Lung Cancer Patients
“BUFFALO, N.Y. —Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.” In light of obesity’s detrimental effects in other cancers, what accounts for those unexpected outcomes?”

Life “Consumed” by Cancer Care: Lung Cancer Patients Spend 1 in 3 Days in Healthcare Contact, Study Finds
“A cancer diagnosis is life-changing event for patients and their families, triggering a cascade of tests and treatments often resulting in frequent, time-consuming healthcare appointments. How many healthcare contact days should patients ideally have? A recent study sought to address this question by examining the number of healthcare contact days for patients with advanced lung cancer. The results were published today in JAMA Network Open. Healthcare contact days refers to days spent receiving healthcare outside of the patient’s home. A high number of healthcare contact days can significantly affect families and caregivers as well as take away from personal time available for patients who may be facing limited life expectancy. The term “time toxicity” has been coined for the large amounts of time taken up healthcare that may interfere with other priorities.”

Lung Cancer Behind Projected 77% Jump in Cancer Cases by 2050
“Even as people around the globe marked World Health Day recently, a new report from the American Cancer Society (ACS) painted a grim picture of just how pervasive cancer will become in the next few decades. Using global data on cancer incidence and death from the Global Cancer Observatory, a World Health Organization (WHO) database, the ACS estimates that the number of people with cancer could rise by 77 percent by 2050. That increase will be driven primarily by population growth – the current global population of roughly 8 billion people is projected to reach 9.7 billion by 2050 – as well as an aging population.”

Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked
“PHILADELPHIA (April 8, 2024) — In a study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that estrogen is metabolized extensively in both mouse and human lungs, ultimately contributing to the development of lung cancer in people who have never smoked. Investigators at Fox Chase are the first to report this finding.”

Nanoparticle Delivery of FZD4 to Lung Endothelial Cells Inhibits Lung Cancer Progression and Metastases
“A recent breakthrough study from the lab of Tanya Kalin, MD, PhD, professor of Child Health and Internal Medicine at the University of Arizona College of Medicine – Phoenix, has shown potential to improve therapeutic outcomes for patients suffering from lung cancers. “We have identified the novel protein FOXF1 that stabilizes blood vessels inside the lung tumors, decreases intertumoral hypoxia and prevents lung cancer metastases,” explained Dr. Kalin, the senior author on this study.”

AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer
“Though a recent Phase III trial failed to achieve its primary endpoint with Imfinzi (durvalumab) in a specific subset of non-small cell lung cancer (NSCLC), AstraZeneca has announced that another Phase III study evaluating the checkpoint inhibitor has demonstrated a survival benefit in patients with limited-state small cell lung cancer (LS-SCLC).”

Study Explores mRNA Vaccine Combo Therapy for Advanced Non-Small Cell Lung Cancer
“In a phase 1B study led by Jhanelle Gray, MD, chair of the Department of Thoracic Oncology at Moffitt Cancer Center, researchers evaluated the use of a messenger RNA-based cancer vaccine to improve upon immune checkpoint blockade therapy in patients with advanced-stage, previously treated NSCLC. “There are a few immune checkpoints we think are important in the therapeutic landscape for non-small cell lung cancer,” Gray said. “Some are further advanced than others, those being anti-PD-1/anti-PD-L1, as well as anti-CTLA-4. But there’s some debate in the field over which patients can receive just one agent, and which need combination therapy.””

Merck puts KRAS cancer drug competitor to the test
“The Phase 3 study, which is set to enroll some 600 people with a common form of metastatic lung cancer, will pit the KRAS inhibitor together with Merck’s immunotherapy Keytruda against Keytruda alone. Researchers will assess whether the combination slows tumor progression and helps people live longer.”

Weekly News Update.
Caring Ambassadors Program provides 3 weekly news updates covering Lung Cancer News, Hepatitis C News, and My Choices© Update. Receive them delivered weekly to your inbox.